Personalized approach to choice-making of an immunoglobulin for the replacement therapy in patients with primary immunodeficiency - is the way to success.

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Immunoglobulin replacement therapy is the most important treatment for the majority of Primary immunodeficiency (PID) forms. It is very important not only to prescribe replacement therapy, but also to choose the appropriate one according to individual patient’s needs at the very moment. Furthermore, in reallife clinical practice some comorbid conditions, which can occur in patient, necessitate the choice of a specific drug from a wide range of IVIG preparations presented on the Russian pharmaceutical market.

Full Text

Restricted Access

About the authors

Tatiana V. Latysheva

NRC Institute of Immunology FMBA of Russia

ORCID iD: 0000-0003-1508-0640

MD, PhD, Professor. The chief оf the department of adult’s immunopathology

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Elena A. Latysheva

NRC Institute of Immunology FMBA of Russia

ORCID iD: 0000-0002-1606-205X

MD, PhD, department of adult’s immunopathology

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Irina A. Manto

NRC Institute of Immunology FMBA of Russia

Author for correspondence.
ORCID iD: 0000-0001-6432-394X

MD, department of adult’s immunopathology

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Nelly H. Setdikova

NRC Institute of Immunology FMBA of Russia

ORCID iD: 0000-0003-2587-7928

MD, PhD, department of adult’s immunopathology

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522


  1. Gupta A. Primary Immunodeficiency Disorders: Where Do We Stand? Indian J Pediatr. 2019;86(10):873-874. doi: 10.1007/s12098-019-03031-1.
  2. Hartono S, Ippoliti MR, Mastroianni M, Torres R, Rider NL. Gastrointestinal Disorders Associated with Primary Immunodeficiency Diseases. Clin Rev Allergy Immunol. 2019;57(2):145-165. doi: 10.1007/s12016-018-8689-9.
  3. Bonilla FA, Khan DA, Ballas ZK et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205. doi: 10.1016/j.jaci.2015.04.049.
  4. Primary Immunodeficiency Diseases./ Ed. Rezaei N., Bonilla FA, Sullivan KE, de Vries E, Orange JS. Berlin, Heidelberg: Publisher: Springer-Verlag Berlin Heidelberg; 2008:38. doi: 10.1007/978-3-540-78936-9_1.
  5. Primary Immunodeficiency Diseases. Ed. Rezaei N, Aghamohammadi A, Notarangelo LD. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017:244. doi: 10.1007/978-3-662-52909-6_3.
  6. Fried AJ, Bonilla FA. Pathogenesis, Diagnosis, and Management of Primary Antibody Deficiencies and Infections. Clin Microbiol Rev. 2009;22(3):396-414. doi: 10.1128/CMR.00001-09.
  7. Quartier P, Debré M, De Blic J et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. J Pediatr. 1999;134(5):589-596. doi: 10.1016/S0022-3476(99)70246-5.
  8. World Health Organization. World Health Organization Model List of Essential Medicines 21st List. Published 2019. Avaliable at 29.05.2020.
  9. Eropean Medicines Agency. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). Available at 29.05.2020.
  10. Garbett ND, Currie DC, Cole PJ. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia. Clin Exp Immunol. 1989;76(1):1-7.
  11. García Rodríguez C, López Trascasa M, Ferreira Cerdán A, Fontán Casariego G. Treatment of primary immunodeficiencies with intravenous gamma globulin. An Esp Pediatr. 1987;27(6):411-415.
  12. Perez EE, Orange JS, Bonilla F et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3):S1-S46. doi: 10.1016/j.jaci.2016.09.023.
  13. Eijkhout HW, van der Meer JWM, Kallenberg CGM et al. The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients with Primary Hypogammaglobulinemia. Ann Intern Med. 2001;135(3):165. doi: 10.7326/0003-4819-135-3-200108070-00008.
  14. Ochs HD, Pinciaro PJ. Octagam® 5%, an Intravenous IgG Product, Is Efficacious and Well Tolerated in Subjects with Primary Immunodeficiency Diseases. J Clin Immunol. 2004;24(3):309-314. doi: 10.1023/B:JOCI.0000025453. 23817.3f.
  15. Stein MR, Nelson RP, Church JA et al. Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies. J Clin Immunol. 2009;29(1):137-144. doi: 10.1007/s10875-008-9231-2.
  16. Goudouris ES, Silva AM do R, Ouricuri AL et al. II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies. Einstein (São Paulo). 2017;15(1):1-16. doi: 10.1590/s1679-45082017ae3844.
  17. Kondratenko IV, Bologov AA. Vnutrivennye immunoglobuliny ot sozdaniya do nashih dnej. Pediatriya Zhurnal im. G.N. Speranskogo. 2018;(6):124-132 [In Russ.].
  18. Latysheva TV, Latysheva EA, Martynova IA. Mesto immunoglobulinov dlya vnutrivennogo vvedeniya v sovremennoi klinicheskoi praktike: Prividzhen – novyi 10% immunoglobulin [A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin]. Ter Arkh. 2016;88(4):82-87. doi: 10.17116/terarkh201688482-87 [In Russ.].
  19. Abramova IN, Rodina YA, Shcherbina AY Intravenous immunoglobulin preparations evolution and their clinical use in pediatric practice. Pediatriya Zhurnal im. G.N. Speranskogo. 2019;(4):210-217. doi: 10.24110/0031-403X-2019-98-4-210-217 [In Russ.].
  20. João C, Negi VS, Kazatchkine MD, Bayry J, Kaveri S V. Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies. J Immunol. 2018;200(6):1957-1963. doi: 10.4049/jimmunol.1701271.
  21. Instrukciya po primeneniyu lekarstvennogo preparata dlya medinskogo primeneniya oktagam. [In Russ.]. Available at 29.05.2020.
  22. Instrukciya po medicinskomu primeneniyu preparata oktagam 10%. [In Russ.]. Available at 29.05.2020.
  23. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicisnkogo primeneniya Gabriglobin-IgG. [In Russ.]. Available at 29.05.2020.
  24. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Gamuneks-S. [In Russ.]. Available at 29.05.2020.
  25. Instrukciya po medicisnkomu primeneniyu preparata I.G. Vena. [In Russ.]. Available at 29.05.2020.
  26. Instrukciya po primeneniyu lekarstvennogo preparata dlya medinskogo primeneniya Imbioglobulin. [In Russ.]. Available at 29.05.2020.
  27. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Immunovenin. [In Russ.]. Available at 29.05.2020.
  28. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Immunovenin.[In Russ.]. Available at 29.05.2020.
  29. Instrukciya po primeneniyu lekarstvennogo preparata dlya medinskogo primeneniya Intratekt. [In Russ.]. Available at 29.05.2020.
  30. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicisnkogo primeneniya Prividzhen. [In Russ.]. Available at 29.05.2020.
  31. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicisnkogo primeneniya Immunoglobulin Sigardis. [In Russ.]. Available at 29.05.2020.
  32. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicisnkogo primeneniya Immunoglobulin Sigardis-MT. [In Russ.]. Available at 29.05.2020.
  33. Instrukciya po primeneniyu Flebogamma 5%. [In Russ.]. Available at 29.05.2020.
  34. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin Replacement Therapy in Children. Immunol Allergy Clin North Am. 2008;28(4):833-849. doi: 10.1016/j.iac.2008.07.001.
  35. Latysheva EA, Latysheva TV, Martynova IA. Evaluation of efficacy and safety of intravenous immunoglobulin IG VENA in patients with primary antibody synthesis immunodeficiency. Russian Journal of Allergy. 2016;(1):16-22 [In Russ.].
  36. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98(1):12-28. doi: 10.1111/j.1423-0410.2009.01226.x.
  37. Laursen IA, Blou L, Sullivan JS, Bang P, Balstrup F, Houen G. Development, Manufacturing and Characterization of a Highly Purified, Liquid Immunoglobulin G Preparation from Human Plasma. Transfus Med Hemotherapy. 2014;41(3):205-212. doi: 10.1159/000357982.
  38. Kirgizov KI, Skorobogatova EV. Intavenous Immunoglobulins: application of modern physiological solutions is able to improve results of the therapy. Russian Journal of Pediatric Hematology and Oncology. 2015;2(2):77-83. [In Russ.].
  39. Wasserman RL. Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency. Immunol Allergy Clin North Am. 2019;39(1):95-111. doi: 10.1016/j.iac.2018.08.001.
  40. IUIS/WHO notice. Appropriate uses of human immunoglobulin in clinical practice. Clin Exp Immunol. 1983;52(2):417-422.
  41. Sklar EM, Quencer RM, Bowen BC, Altman N, Villanueva PA. Magnetic resonance applications in cerebral injury. Radiol Clin North Am. 1992;30(2):353-366. DOI: 1535861.
  42. Brown KE, Young NS. Parvoviruses and Bone Marrow Failure. Stem Cells. 1996;14(2):151-163. doi: 10.1002/stem.140151.
  43. Adams STM, Schmidt KM, Cost KM, Marshall GS. Common Variable Immunodeficiency Presenting With Persistent Parvovirus B19 Infection. Pediatrics. 2012;130(6):e1711-e1715. doi: 10.1542/peds.2011-2556.
  44. Ruiz Gutiérrez L, Albarrán F, Moruno H, Cuende E. Parvovirus B19 chronic monoarthritis in a patient with common variable immunodeficiency. Reumatol Clínica. 2015;11(1):58-59. doi: 10.1016/j.reuma.2014.07.001.
  45. Dichtelmüller HO, Biesert L, Fabbrizzi F et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion. 2009;49(9):1931-1943. doi: 10.1111/j.1537-2995.2009.02222.x.
  46. Kühnel D, Müller S, Pichotta A, Radomski KU, Volk A, Schmidt T. Inactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma-derived products and pasteurization of human serum albumin. Transfusion. 2017;57(3pt2):802-810. doi: 10.1111/trf.13964.
  47. Rabenau HF, Biesert L, Schmidt T, Bauer G, Cinatl J, Doerr HW. SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation. Biologicals. 2005;33(2):95-99. doi: 10.1016/j.biologicals.2005.01.003.
  48. Octapharma. Koronavirus i bezopasnost’ lekarstvennyh preparatov, poluchaemyh iz plazmy krovi. Pediatriya Segodnya. 2020;(2):11 (In Russ.)].
  49. Abolhassani H, Asgardoon MH, Rezaei N, Hammarstrom L, Aghamohammadi A. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol. 2015;11(11):1229-1243. doi: 10.1586/1744666X.2015.1079485.
  50. Vitiello G, Emmi G, Silvestri E, Di Scala G, Palterer B, Parronchi P. Intravenous immunoglobulin therapy: a snapshot for the internist. Intern Emerg Med. 2019;14(7):1041-1049. doi: 10.1007/s11739-019-02150-z.
  51. Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013;9(6):577-587. doi: 10.1586/eci.13.39.
  52. Sun AK, Wu Y, Pot G et al. Glycine and L-proline Demonstrate Similar IgG Stabilization in Liquid Immunoglobulin Intravenous 10% (IGIV) Formulations. J Allergy Clin Immunol. 2011;127(2):AB18-AB18. doi: 10.1016/j.jaci.2010.12.081.
  53. Dantal J. Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk. Am J Nephrol. 2013;38(4):275-284. doi: 10.1159/000354893.
  54. Mallick R, Hubsch A, Barnes DG. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening. Transfusion. 2018;58(12):2752-2756. doi: 10.1111/trf.14918.
  55. Frenzel W, Wietek S, Svae T-E, Debes A, Svorc D. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016;54(11):847-855. doi: 10.5414/CP202782.

Supplementary files

Supplementary Files
1. Figure1. The most important IVIG characteristics (the survey «Primary immunodeficiency. The usage of IVIG» of 86 RAACI members)

Download (60KB)
2. Figure 2. Steps of virus safety assurance in modern normal human immunoglobulins

Download (44KB)
3. Figure 3. Control over infections in Patients with PID, receiving replacement therapy with Octagam 5% and Octagam 10%

Download (34KB)
4. Figure 4. The results of “Primary immunodeficiency. The usage of IVIG” survey among the members of RAACI: a) How do you think, which product has the smallest number of side effects? b) What product would you chose if there is choice?

Download (42KB)

Copyright © Pharmarus Print Media, 2020

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies